Cameron Reynolds, CEO of Volition Rx, the NYSE-listed company, brings Proactive Investors London an end of quarter catch up with newsflows in three key areas. First there's more news on their new routine blood test to screen for colorectal and prostate cancers which has reduced the need for more invasive colonoscopies and biopsies. Secondly, there's an update on the potential for further revenue streams for Volition once discovery grade assets convert to product grade opportunities. And lastly, how Volition continues to push into veterinary medicine while both well funded and keeping costs down.
Growth 'guaranteed' for a well funded Volition Rx
Quick facts: VolitionRx
Price: 3.67 USD
Market Cap: $169.65 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE